新的抗癌药物QLS32015显示,在治疗复发性多重骨髓瘤方面,76.9%的疗效有效。 New anticancer drug QLS32015 shows 76.9% effectiveness in treating relapsed multiple myeloma.

在美国血病学学会第66次年会上,初步结果表明,基卢制药公司新的抗癌症药物QLS32015有效治疗复发/耐药性多重骨髓瘤。 At the 66th Annual Meeting of the American Society of Hematology, preliminary results showed Qilu Pharmaceutical's new anticancer drug, QLS32015, effectively treats relapsed/refractory multiple myeloma. 第一阶段的试验表明,该药物是针对五氯环乙烷和CD3的,其客观答复率为76.9%,并被患者充分发配。 The Phase I trial indicated the drug, which targets GPRC5D and CD3, had an objective response rate of 76.9% and was well-tolerated by patients. 常见副作用包括低等级细胞素释放综合征和血病学问题,没有严重神经毒性的报告。 Common side effects included low-grade cytokine release syndrome and hematological issues, with no severe neurotoxicity reported. 该研究继续评估最佳剂量。 The study continues to assess optimal dosing.